The long non-coding RNA <i>Cancer Susceptibility 15</i> (<i>CASC15</i>) is induced by isocitrate dehydrogenase (IDH) mutations and maintains an immature phenotype in adult acute myeloid leukemia

Isocitrate Dehydrogenase Mutations in Myelodysplastic Syndromes and in Acute Myeloid Leukemias

“…A very recent study provided evidence about a possible implication of long-non coding RNAs (lncRNAs) in the pathogenesis of differentiation block induced by IDH mutants in leukemia [ 111 ]. The expression of lncRNA Cancer Susceptibility CASC15 is inversely correlated with myeloid differentiation and is overexpressed in AMLs bearing IDH and TET2 mutations [ 111 ]. CASC15 expression is higher in AMLs bearing IDH mutations without concomitant DNMT3A mutations compared to that observed in AMLs bearing both mutations [ 112 ].…”

“…CASC15 expression is higher in AMLs bearing IDH mutations without concomitant DNMT3A mutations compared to that observed in AMLs bearing both mutations [ 112 ]. CASC15 expression was higher in IDH2-R140 -mutant AMLs, compared to IDH1-R132 - and IDH2-R172 -mutant AMLs [ 111 ]. Introduction of mutant IDH in experimental models induced a marked enhancement of lncRNA CASC15 [ 111 ].…”

“…CASC15 expression was higher in IDH2-R140 -mutant AMLs, compared to IDH1-R132 - and IDH2-R172 -mutant AMLs [ 111 ]. Introduction of mutant IDH in experimental models induced a marked enhancement of lncRNA CASC15 [ 111 ].…”

Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia

“…Only a few of these genes had a previously ascribed role in AML pathogenesis and/or chemoresistance. Namely, CASC15 which may act as a proto-oncogene affecting proliferation and differentiation, 14 KDM7A that is a lysine-specific histone demethylase involved in cell differentiation and resistance to chemotherapy, 15 and IGFBP2 that is associated with chemoresistance. 16 Interestingly, none of the 15 genes differentially expressed in persisting leukaemic cells and predictive of inferior OS in the FLUGAZA trial was prognostic in the BeatAML cohort (Table S3).…”

“…Sara Villar 1 Beñat Ariceta 1 Juan-José Garcés 1 Leire Burgos 1 Diego Alignani 1 Sarai Sarvide 1 David Martínez-Cuadrón 2 Juan-Miguel Bergua 3 Susana Vives 4 Lorenzo Algarra 5 Mar Tormo 6 Pilar Martinez 7 Josefina Serrano 8 Pilar Herrera 9 Fernando Ramos 10 Olga Salamero 11 Esperanza Lavilla 12 Cristina Gil 13 Jose-Luis Lopez-Lorenzo 14 Maria-Belen Vidriales 15 Carmen Chillon 15 Jorge Labrador 16 Jose-Francisco Falantes 17 María-José Sayas 18 Rosa Ayala 7 Joaquin Martinez-Lopez 7 Ana Alfonso Pierola 1 Maria-Jose Calasanz 1,19 Felipe Prosper…”